The EMIS article you cited from Seeking Alpha is clueless. Not halting a trial after an interim look does not imply that “we are hitting our primary endpoints,” as the Seeking Alpha author asserts.
EMIS is one of those biotech companies that’s been a day late and a dollar short with respect to every clinical program it has conducted. There could be some upside for shareholders if oral calcitonin eventually pans out—provided that EMIS is still financially solvent when that happens. My advice, FWIW, is to pass.
From a financial standpoint, the oral-calcitonin program was* immaterial for NVS but highly consequential for EMIS, who is another biotech that can’t seem to do anything right.
Market Data 
Markets 
AI
